Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

113
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
113

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay.

ESMO open·2025
Same author

Imaging for local recurrence of breast cancer.

Journal of cancer research and clinical oncology·2024
Same author

Primary hepatic metastatic epitheloid trophoblastic tumor of the uterus treated with multimodal therapy including pembrolizumab and thermoablation. Case report of an extremely rare disease and review of the literature.

Gynecologic oncology reports·2023
Same author

The German Network for Personalized Medicine to enhance patient care and translational research.

Nature medicine·2023
Same author

Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry.

ESMO open·2023
Same author

Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.

ESMO open·2022
Same journal

Consensus on the Management of Inavolisib Side Effects. A Survey on Defined Side Effects, the Assumed Pathomechanism, Preventative and/or Therapeutic Measures Including the Integration of Additional Health Care Professionals - a Consensus Paper.

Geburtshilfe und Frauenheilkunde·2026
Same journal

Statement by the Uterus Commission of the Arbeitsgemeinschaft Gynäkologische Onkologie [German Gynecological Oncology Group] (AGO) on the ESGO-ESTRO-ESP Guideline 2025.

Geburtshilfe und Frauenheilkunde·2026
Same journal

Feasibility of <i>PIK3CA</i> Mutation Detection via Microfluidic Isolation of Disseminated Tumor Cells from Bone Marrow in Breast Cancer Patients.

Geburtshilfe und Frauenheilkunde·2026
Same journal

Stereotactic Vacuum-Assisted Biopsy in Photon-Counting Dedicated Spiral Breast CT: A Proof of Concept.

Geburtshilfe und Frauenheilkunde·2026
Same journal

RSV Prophylaxis in Neonates: Implementation and Parental Acceptance during the First RSV Season in Germany.

Geburtshilfe und Frauenheilkunde·2026
Same journal

Genital Herpes Simplex Virus (HSV) Infection During Pregnancy - Recommendations of the Working Group on Obstetrics and Prenatal Medicine (AGG - Section on Maternal Disorders).

Geburtshilfe und Frauenheilkunde·2026
See all related articles

Related Experiment Video

Updated: Apr 7, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K

Bone-Targeted Therapy.

J Salmen1, M Banys-Paluchowski2, T Fehm1

  • 1Universitätsfrauenklinik Düsseldorf, Heinrich-Heine Universität Düsseldorf, Düsseldorf.

Geburtshilfe Und Frauenheilkunde
|July 14, 2015
PubMed
Summary
This summary is machine-generated.

Bisphosphonates and denosumab are key osteoporosis and bone metastasis treatments. Post-menopausal women may benefit from adjuvant bisphosphonates for breast cancer, guided by current guidelines.

Keywords:
adjuvant therapybisphosphonatesbone metastasesbreast cancerdenosumabosteoporosis

More Related Videos

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.7K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Related Experiment Videos

Last Updated: Apr 7, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K
Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model
05:08

Targeted and Selective Treatment of Pluripotent Stem Cell-derived Teratomas Using External Beam Radiation in a Small-animal Model

Published on: February 17, 2019

6.7K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metabolism

Background:

  • Bisphosphonates and denosumab are established treatments for osteoporosis and bone metastases.
  • The role of these agents in adjuvant breast cancer therapy is debated due to varied data.
  • Evidence suggests post-menopausal women specifically benefit from adjuvant bisphosphonates.

Approach:

  • This review discusses the clinical significance of osteoprotective therapy.
  • Focus is placed on both metastatic and adjuvant settings in cancer care.
  • Current guidelines from the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) on osteo-oncology are central.

Key Points:

  • Osteoprotective therapies like bisphosphonates and denosumab have defined roles in bone health management.
  • Adjuvant bisphosphonate use in breast cancer shows particular benefit for post-menopausal women.
  • Heterogeneous data necessitates careful consideration of treatment strategies.

Conclusions:

  • Osteoprotective therapy is clinically relevant in both metastatic and adjuvant cancer scenarios.
  • Recommendations are informed by the latest AGO guidelines for osteo-oncology and bone health.
  • Further research may clarify optimal use in diverse patient populations.